Katherine E. Reeder-Hayes, MD, MBA, MSc (IMAGE)
Caption
"I hope our study will help expand the framework that we use to make these decisions from one where we just think about the biologic action of the drug to one where we also consider the bigger picture of what the treatment experience is like for the patient, including their financial burden, investment of time, and side effects,” said Katherine Reeder-Hayes, MD, MBA, MSc. “The most potent drug isn’t always the next best choice depending on what the patient values and wants to accomplish with their treatment.”
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content